Surrozen, Inc. (SRZN)
- Previous Close
8.61 - Open
8.14 - Bid --
- Ask --
- Day's Range
8.14 - 8.98 - 52 Week Range
4.50 - 16.19 - Volume
11,124 - Avg. Volume
16,966 - Market Cap (intraday)
28.725M - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
-- - EPS (TTM)
-21.33 - Earnings Date Apr 29, 2024 - May 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.00
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.
www.surrozen.comRecent News: SRZN
Performance Overview: SRZN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SRZN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SRZN
Valuation Measures
Market Cap
28.72M
Enterprise Value
-3.94M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.76
Enterprise Value/Revenue
-0.12
Enterprise Value/EBITDA
0.10
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.69%
Return on Equity (ttm)
-75.56%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-43.04M
Diluted EPS (ttm)
-21.33
Balance Sheet and Cash Flow
Total Cash (mrq)
36.04M
Total Debt/Equity (mrq)
8.91%
Levered Free Cash Flow (ttm)
-23.48M